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produces. These include enterotoxins and colonization fac-
tors apart from other antigens like the lipopolysaccharide
(LPS), which are part of the ‘O’ antigen. Over 100 types
of ‘O’ groups have been detected in ETEC strains in com-
bination with different ﬂagellar (H) antigens, that together
make the serotype (O:H) of the bacteria. Although exten-
sive efforts have been made to determine the prevalence of
the toxins and colonization factors in ETEC strains isolated
in different regions of the world, relatively little is known
about the serotype of the bacteria circulating in different
countries, especially those that are prevalent at this time.
Recent epidemiological studies have shown that ETEC
strains from different regions differ in their phenotypic char-
acteristics. These ﬁndings are important to determine which
vaccines would be suitable for use in one region but not in
another as a measure of protection against ETEC infections.
ETEC isolated from two geographically different locations,
Mexico and Bangladesh, have been characterized for their
‘O’ and ‘H’ antigens as well as for their enterotoxin types
and colonization factor production. Overall a variety of
ETEC phenotypes were found to be present in both set-
tings. Twelve serotypes were common in both settings. A few
serogroups were only present in isolates from Bangladesh
(O20, O115, O126, O128, O114), while others were present
only in strains isolated in Mexico (O103, O170, O22). The pre-
dominant colonization factors in both settings were CFA/I,
CS5+CS6, CS6 as well as CS1+CS2/CS3. Colonization factors
were produced by strains belonging to a few ‘O’ serogroups,
CFA/I (O126 and O128), CS5+CS6 (O115 and O167), CS6
(O169), CS1+CS2/CS3 (O6). Based on these results, formu-
lation of an effective multivalent ETEC vaccine will have to
include not only the major colonization factors and LT tox-
oid but also the LPS of important serogroups. An inactivated
killed ETEC vaccine that has undergone extensive testing
includes strains of serogroups O6, O25, O78 and O167. Based
on the present data this vaccine would in addition need the
incorporation of strains belonging to serogroups O115 and
O126 to be more effective in the protection against the most
common cause of bacterial diarrhea in early childhood and
the second most predominant cause of diarrhea in adults
in endemic countries, including tourists travelling to these
areas.
doi:10.1016/j.ijid.2008.05.051
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Typhoid Vaccines as Routine Public Health Tools for
Developing Countries: An Idea Whose Time Has Come
J. Clemens
International Vaccine Institute, Seoul, Republic of Korea
Despite the availability of two internationally licensed,
newer generation typhoid vaccines that are safe and effec-
tive and despite an annual global typhoid mortality burden
estimated at over 200,000 deaths, typhoid vaccines are not
routinely used as public health interventions in develop-
ing countries with high typhoid burdens. Although there are
multiple reasons for the failure to introduce these vaccines
into public health programs for the poor, a gap in evi-
dence to inform vaccine policy is a major factor. To address
this gap in evidence, the International Vaccine Institute,
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ith the support of the Bill and Melinda Gates Foundation,
as coordinated a multi-country, multidisciplinary program
f research, called the Diseases of the Most Impoverished
DOMI) Program, to inform policy about typhoid vaccine
ntroduction in Asia. This research program, which has been
ndertaken in Bangladesh, China, India, Indonesia, Pakistan,
nd Vietnam, has demonstrated the burden of typhoid fever
o be high, but geographically heterogeneous. The research
as also demonstrated a high ﬁnancial cost associated with
yphoid fever, and a modest cost of purchasing and deliv-
ring one of the two currently available, internationally
icensed typhoid vaccines (Vi polysaccharide). Demonstra-
ion projects with Vi vaccine have shown that the vaccine is
easibly delivered in mass immunization campaigns in both
chool and community settings, and when delivered in these
ampaigns the vaccine confers both direct and herd protec-
ion. As well, there is a high population demand for a vaccine
ith the cost and characteristics of Vi polysaccharide, and
ven a willingness on the part of developing country popu-
ations to pay for this vaccine, particularly for vaccination
f children. In aggregate, these ﬁndings have helped to
otivate a recently published, strengthened WHO recom-
endation for routine typhoid vaccination in settings with
igh typhoid disease burdens.
oi:10.1016/j.ijid.2008.05.052
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he New Emerging Strain of Cholera: One Step Ahead of
enomics
. Balakrish Nair
National Institute of Cholera and Enteric Diseases, Kolkata,
ndia
remarkable event in recent years has been the emergence
f strains of Vibrio cholerae O1 that possess traits of both
he classical and El Tor biotypes. These strains were ﬁrst
ncountered from sporadic cases of cholera isolated from
992 onwards in Matlab, Bangladesh. Phenotypic and geno-
ypic traits failed to categorize these strains into classical
r El Tor biotype and were designated as the Matlab vari-
nts. The Matlab variants assumed greater signiﬁcance when
trains of V. cholerae O1 isolated from Beira, Mozambique
n 2005 displayed typical traits of the El Tor biotype but car-
ied the classical CTX prophage. A more recent analysis of
. cholerae O1 strains isolated in Bangladesh during the past
our and a half decades revealed that from 2001 onwards
ll strains associated with cholera belonged to the El Tor
iotype but produced classical cholera toxin (CT) which was
ifferent from the prototype El Tor biotype that produced
l Tor CT. This new variant of the El Tor biotype is now
ominant in several other countries. At this time, it is not
ertain whether the change in CT subtype in the El Tor strains
ill enhance their epidemic potential. Given that there are
ifferences between the classical and El Tor biotypes, the
election of the El Tor biotype which produces classical CT
ould seem to indicate an evolutionary optimization of the
l Tor biotype and represents a new more efﬁcient emerging
orm of the El Tor biotype. Under the cholera surveillance
rogram of the International Centre for Diarrheal Disease
esearch in Bangladesh, an increasing trend in the number
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studied toward potential beneﬁcial application of statins.
The present talk will give an overview of animal models of
infection with respect to effects of statin treatment.
doi:10.1016/j.ijid.2008.05.0566 13th Internat
f cholera patients as well as in the severity of the disease
as been observed. Globally, also there has been a substan-
ial increase in the incidence of cholera and in the number
f outbreaks of cholera.
oi:10.1016/j.ijid.2008.05.053
.004
otavirus and Rotavirus Vaccines: Are We There Yet?
. Glass
Director, Fogarty International Center, Bethesda, MD, USA
otavirus vaccines currently licensed in more than 90 coun-
ries hold the promise of preventing more than 600,000
iarrhea deaths and many hospitalizations and doctor vis-
ts worldwide. The positive impact of vaccination programs
s just becoming evident in US and middle income countries
f Latin America and as yet, no major danger signs such
s intussusception have clouded the horizon. At the same
ime, the efﬁcacy of these new rotavirus vaccines has not
een demonstrated in poor developing countries and some
minous signs are appearing that are cause for concern. The
mmune response to the GSK vaccine in infants in S. Africa
nd Bangladesh has been substantially less than that mea-
ured in studies in Latin America, the US and Finland and
his difference may be reﬂected in lower efﬁcacy. Trials now
ngoing should determine the efﬁcacy in two populations in
ub-Saharan Africa. The reasons for this impaired immune
esponse are numerous - high titers of maternal antibody,
reast feeding practices, and interfering gut ﬂora, micronu-
rient deﬁciency- to name a few and ways to address these
ssues will be key to either improving these vaccines or to
ejecting them should the results of ongoing ﬁeld trials prove
isappointing. To date, no serious discussion has been given
o the level of efﬁcacy that the international community
ould deem acceptable for rotavirus vaccines to receive
global recommendation from WHO. Research is needed
oday to identify the cause of the low immune responses
nd to identify strategies to improve this problem. Insur-
nce policies to consider new vaccines should be considered
s well so that alternative vaccine candidates are in the
ings should they be needed.
oi:10.1016/j.ijid.2008.05.054
eyond Cardiovascular Disease: Statins and Cholesterol in
nfectious Diseases (invited)
.001
tatins and Sepsis: Multiple Modiﬁcations at Multiple
evels
. Terblanche
Guy’s & St Thomas’ NHS Trust, London, United Kingdom
ortality from sepsis is a leading cause of death world-
ide. Clinical observational studies of the effect of statins
n reducing the morbidity and mortality of sepsis suggest a
revention, and possible treatment, effect. Effects at the
ranscriptional level lead to the reduced expression of var-
ous inﬂammatory mediators by leukocytes and endotheliall Congress on Infectious Diseases Abstracts (Invited Papers)
ells. Heme oxygenase induction has anti-oxidant, anti-
nﬂammatory, and cytoprotective effects. Direct blockade
lters leukocyte-endothelial cell interaction, while reduced
xpression of MHC-II affects T-cell function. That statins do
ot target individual inﬂammatory mediators, but possibly
educe the overall magnitude of the systemic response, may
rove an important distinguishing feature modulating the
ost response to septic insults.
oi:10.1016/j.ijid.2008.05.055
.002
tatins in Animal Models of Infection
.W. Merx
Dep. of Cardiology, Pneumology and Vascular Medicine,
WTH University-Hospital, Aachen, Germany
tatins, are effective lipid lowering agents used extensively
n medical practice. Recent statin studies have extended
tatin therapy to the acute manifestations of cardiovas-
ular disease and have suggested cholesterol independent
herapeutic beneﬁts, termed ‘‘pleiotropic’’ effects, which
ave added a wide scope of potential targets for statin
herapy. Since the approval for clinical use in humans of
ovastatin as the ﬁrst statin several statins have become
ommercially available including pravastatin, simvastatin,
uvastatin, atorvastatin, cerivastatin (withdrawn in 2001),
itavastatin and rosuvastatin. While all these statins share
MG-CoA reductase inhibition as common mechanism of
ction, they differ in absorption, afﬁnity, binding, solubil-
ty and excretion. Apart from causing variations in efﬁcacy
f cholesterol lowering between the agents, differences in
hese pharmacologic properties might also be relevant with
espect to so called ‘‘pleiotropic’’ effects of statins. These
‘pleiotropic’’ effects include anti-inﬂammatory and antiox-
dative properties, improvement of endothelial function and
ncreased nitric oxide bioavailability and thus might con-
ribute to the beneﬁt observed with statin therapy. Notably,
hese important immunomodulatory effects of statins have
een demonstrated to be independent of lipid lowering and
ppear to be mediated via interference with the synthesis
f mevalonate metabolites (nonsteroidal isoprenoid prod-
cts). In addition, mechanisms for anti-inﬂammatory actions
f statins have been revealed that are not related to the
soprenoid metabolism. For instance, it has been identiﬁed
hat some statins act as direct antagonists of LFA-1 due to
heir capacity to bind to the regulatory site in the LFA-1
-domain. Several animal models of infection ranging from
acterial, and fungal to viral causative agents have been
